A Comparison of Efficacy of Two Brands of Enoxaparin in COVID-19 Patients: A Pilot Study
Asian Journal of Medicine and Health,
Page 135-140
DOI:
10.9734/ajmah/2022/v20i11752
Abstract
Introduction: Enoxaparin is a complex and biologically derived low-molecular-weight Heparin which is approved for a variety of clinical indications associated with thromboembolic events such as Deep Vein Thrombosis and Venous Thromboembolism. During COVID-19 it was frequently used as prophylaxis in the treatment of thromboembolic events. Nowadays, many brands have come up in the market for the same.
Objective: In Tricolour Hospital located in Vadodara, Gujarat, the ongoing brand of Enoxaparin 0.6 i.e., Clexane (Sanofi) falls short as well as in the pharmaceutical market. Hence, the management decided to procure another brand of Enoxaparin until Clexane is available to the vendors. Therefore, the present study was planned to study efficacy of two brands of Enoxaparin –one is Coguparine, (Venus Pharmaceuticals) and another LMWX- (Abbott) in COVID-19 patients in an isolation ward of hospital. The aim of present study was to compare the efficacy of two brands of Enoxaparin (Coguparine vs LMWX) for prophylactic treatment of thromboembolism observed in COVID-19 patients.
Methodology: Patients were randomly divided into 2 groups- A and B. Patients in group A received Coguparine while patients in group B received LMWX. Statistical analysis was carried out using paired t-test.
Results: The laboratory reports of patients in Group-A presented few abnormal improvements in the Complete blood count but there was no concrete evidence about the same. On the other hand, patients in Group-B receiving LMWX showed improvement in CBC profile. Also, there was significant difference observed in C-Reactive Protein and D-Dimer profiles in both the brands.
Conclusion: This showed that for the cost-effective treatment and procurement of Enoxaparin there is no harm in using generic formulation of Enoxaparin as and when required. But LMWX was proved to be of standard quality in terms of efficacy.
Keywords:
- Enoxaparin
- LMWX
- coguparine
- COVID-19
- complete blood count
- efficacy
How to Cite
References
DOI: 10.1111/dom.14124. Epub 2020 Jul 16. PMID: 32573903; PMCID: PMC7361304.
Mondal S, Quintili AL, Karamchandani K, Bose S. Thromboembolic disease in COVID-19 patients: A brief narrative review. J Intensive Care. 2020;8:70.
DOI: 10.1186/s40560-020-00483-y. PMID: 32939266; PMCID: PMC7487447.
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834-847.
DOI: 10.1002/ajh.25829. Epub 2020 May 23. PMID: 32282949; PMCID: PMC7262337.
Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;99(6):1205-1208.
DOI: 10.1007/s00277-020-04019-0. Epub 2020 Apr 15. PMID: 32296910; PMCID: PMC7156897.
Słomka A, Kowalewski M, Żekanowska E. Coronavirus Disease 2019 (COVID-19): A Short Review on Hematological Manifestations. Pathogens. 2020;9(6):493.
DOI: 10.3390/pathogens9060493. PMID: 32575786; PMCID: PMC7350358.
Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J Allergy Clin Immunol. 2020;146(1):1-7.
DOI: 10.1016/j.jaci.2020.04.021. Epub 2020 Apr 25. PMID: 32344056; PMCID: PMC7194727.
Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332-334.
DOI: 10.1016/j.medmal.2020.03.007. Epub 2020 Mar 31. PMID: 32243911; PMCID: PMC7146693.
Shah S, Shah K, Patel SB, Patel FS, Osman M, Velagapudi P, Turagam MK, Lakkireddy D, Garg J. Elevated d-dimer levels are associated with increased risk of mortality in coronavirus disease 2019: A systematic review and meta-analysis. Cardiol Rev. 2020;28(6):295-302.
DOI: 10.1097/CRD.0000000000000330. Epub 2020 Jul 2. PMID: 33017364; PMCID: PMC7437424.
Miesbach W, Makris M. COVID-19: Coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost. 2020;26: 1076029620938149.
DOI: 10.1177/1076029620938149. PMID: 32677459; PMCID: PMC7370334.
clinicaltrials.gov/ct2/show/NCT04646655 [last cited on 30/11/2021]
Casella IB, Puech-Leão P. Generic versus branded enoxaparin in prophylaxis and treatment of vein thrombosis. Rev Assoc Med Bras (1992). 2015;61(1):44-50.
DOI: 10.1590/1806-9282.61.01.044. Epub 2015 Jan 1. PMID: 25909208.
Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown IB, Goodman SG, Mahaffey KW, Cohen M, McCabe CH, Antman EM, Braunwald E. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: A meta-analysis. Eur Heart J. 2007;28(17):2077-86.
DOI: 10.1093/eurheartj/ehm224. Epub 2007 Jun 28. PMID: 17600038.
Walenga JM, Jeske WP, Hoppensteadt D, Cunanan J, Khan H, Escalante V, Fareed J, Bakhos M. Comparative studies on branded enoxaparin and a US generic version of enoxaparin. Clin Appl Thromb Hemost. 2013;19(3):261-7.
DOI: 10.1177/1076029612463427. Epub 2012 Oct 22. PMID: 23091283.
-
Abstract View: 109 times
PDF Download: 36 times
